DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD

Information source: Shire Pharmaceutical Development
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: ADHD

Intervention: Mixed amphetamine salts (ADDERALL XR) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Shire Pharmaceutical Development

Official(s) and/or principal investigator(s):
Garrick Fiddler, MD, Study Director, Affiliation: Shire Pharmaceutical Development

Summary

Evaluate the behavioral effects of ADDERALL XR versus STRATTERA under controlled conditions utilizing the SKAMP deportment scale.

Clinical Details

Official title: A Randomized, Double-Blind, Parallel-Group, Analog Classroom Study, Evaluating ADDERALL XR Versus STRATTERA, Dosed Once Daily, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD)

Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Change in SKAMP deportment scores from baseline to endpoint (averaged across Days 7, 14, 21)

Secondary outcome:

PERMP, SKAMP attention scale, CGI, CGIS-P, Peds QL

treatment-emergent adverse events

Eligibility

Minimum age: 6 Years. Maximum age: 12 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Primary diagnosis of ADHD combined subtype or predominantly hyperactive-impulsive

subtype, based on psychiatric evaluation

- Capable of understanding and following classroom instructions

- Generally functioning academically at age-appropriate levels

Exclusion Criteria:

- ADHD, predominantly inattentive subtype

- Controlled or uncontrolled comorbid psychiatric diagnosis (except ODD) with

significant symptoms such as PTSD, psychosis, bipolar disease, severe OCD, severe depressive or severe anxiety disorder

- Documented history of aggressive behavior serious enough to preclude participation in

regular classroom activities

- Documented allergies or intolerance to either of the active treatments or tricyclic

antidepressants

Locations and Contacts

Massachusetts General Hospital, Boston, Massachusetts, United States
Additional Information

Synopsis of study results

FDA-approved labelling information, US only

FDA Recall information

FDA Medical product safety alerts

Starting date: August 2003
Ending date: August 2004
Last updated: November 30, 2007

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012